AI assistant
Sending…
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2025
Jan 7, 2025
32254_dirs_2025-01-07_dc0c5e65-2710-4898-8145-78b642d6d134.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2025-01-03
Reporting Person: Zaderej Karen L. (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-01-03 | Stock Option (Right to Buy) | $8.26 | A | 40000.00 | Acquired | 2035-01-03 | Common Stock (40000.00) | Direct |
More from EyePoint Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Investor Presentation
2026
Apr 13
Director's Dealing
2026
Mar 24
Legal Proceedings Report
2026
Mar 20
Regulatory Filings
2026
Mar 4
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 18
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Jan 7